Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aequus PharmaceuticalsAQSZF 5-Year Yield-on-Cost % is 0.00 as of Aug. 16, 2026. The stock has 6 warning signs investors should review. Among 510 Drug Manufacturers companies, Aequus Pharmaceuticals ranks worse than 196078.24% on this metric.
Aequus Pharmaceuticals's yield on cost for the quarter that ended in Sep. 2025 was 0.00.
The historical rank and industry rank for Aequus Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
AQSZF's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.285 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Aequus Pharmaceuticals 5-Year Yield-on-Cost % Related Terms
AQSZF vs GRPS, GCAN, STEK: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aequus Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aequus Pharmaceuticals 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aequus Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Aequus Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Aequus Pharmaceuticals (AQSZF) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 16, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Aequus Pharmaceuticals and its competitors. According to the industry distribution chart, Aequus Pharmaceuticals ranks #999999 out of 510 companies in the Drug Manufacturers industry.
Is Aequus Pharmaceuticals' 5-Year Yield-on-Cost % too high?
Aequus Pharmaceuticals' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Aequus Pharmaceuticals ranks #999999 out of 510 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Aequus Pharmaceuticals' 5-Year Yield-on-Cost % compare to GRPS and GCAN?
According to the Drug Manufacturers industry distribution chart, Aequus Pharmaceuticals ranks #999999 out of 510 companies for 5-Year Yield-on-Cost %. This places Aequus Pharmaceuticals in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Aequus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aequus Pharmaceuticals's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aequus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aequus Pharmaceuticals (AQSZF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 88% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Aequus Pharmaceuticals (AQSZF), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products namely Tacrolimus IR and Vistitan.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AQSZF has been successfully added to your 
